TORONTO, Aug. 8 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, today reported
its results for the second quarter ended June 30, 2006.
"We continue to gain recognition as the logical alternative for imaging
in the operating room and we are meeting our stated milestones. We said we
would have 50 SPY Systems placed by July 2006 and we have achieved exactly
that," said Arun Menawat, President and Chief Executive Officer of Novadaq
Technologies Inc. "We also filed for CE Mark approval for the OPTTX System
which will enable a limited launch of this product in Europe by the end of
this year. For the LUNA System, we completed animal studies and recently
shipped a LUNA System to the University of Rochester for use in a human
clinical trial."
<<
Selected Second Quarter, 2006 Financial and Operating Highlights
- SPY(R): Received a purchase order for the 50th SPY System in the
United States as of June 30, 2006 - up from 30 Systems at the end of
the first quarter. Procedure based revenues increased by over 50%
from the previous quarter. Received 510(k) pre-market clearance from
the FDA for a labeling revision that gives cardiac surgeons greater
flexibility for the administration of the imaging agent, enhancing
image quality during coronary artery bypass graft (CABG) procedures.
Implemented software and hardware upgrades to the SPY System as part
of our on-going program of responding to user feedback to further
improve product performance and ease of adoption and to increase
revenue.
- OPTTX(R): Filed for CE Mark which would enable us to market the OPTTX
System in Europe.
- LUNA(TM): Completed animal testing as highlighted at the annual
meeting of the American Urological Association held in Atlanta,
Georgia, in May. Shipped a LUNA System to the University of Rochester
for use in a human clinical trial.
>>
Financial Results
Three Months Ended June 30, 2006 "Q2-2006" Compared to Three Months Ended
June 30 2005 "Q2-2005"
Revenue increased to approximately $509,000 in Q2-2006 from approximately
$64,000 in Q2-2005. The increase reflects an increase in procedure based
revenue resulting from the commercial launch of the SPY System in the US.
Procedure based revenue increased by approximately $171,000 or 52% from
Q1-2006 reflecting the growing installed based, and a gradual improvement in
utilization.
Gross profit increased to approximately $297,000 in Q2-2006 from
approximately $23,000 in Q2-2005. As a percentage of sales, gross profit
increased to 58% in Q2-2006 from 36% in Q2-2005 primarily due to increasing
utilization rates of the SPY System. Gross profit in Q2-2006 was approximately
$65,000 higher than in Q1-2006 because the gross profit percentage on capital
sales completed in Q1 was lower than the gross profit percentage on procedural
revenue. In Q2-2006, the commission paid to Sorin is included in sales and
marketing expenses rather than cost of sales. We have reclassified the
presentation of commissions in previous periods shown above, to conform with
current quarter presentation.
Sales and marketing expenses increased by approximately $897,000 to
approximately $1,198,000 in Q2-2006 from approximately $301,000 in Q2-2005 to
support the commercial launch of the SPY System in the US. Significant
increases included the cost of hiring 12 Clinical Educators, increased
commission expense, and increased marketing costs. Sales and marketing
expenses increased by approximately $442,000 from Q1-2006 to Q2-2006 because
the rate of hiring of clinical educators was particularly rapid during that
period, and because sales commissions increased in proportion to the increase
in procedure based revenue. With the exception of sales commissions which will
continue to grow in proportion to revenue, the rate of growth in sales and
marketing expenses is expected to moderate for the balance of 2006.
Research and development expenses increased by approximately $293,000 to
$1,242,000 in Q2-2006 from $949,000 in Q2-2005. The overall increase relates
primarily to increases in patent and trademark expenses to expand Novadaq's
patent portfolio to cover additional applications of its imaging platform,
OPTTX device design and testing costs, and costs associated with the registry
trial and visionary programs for SPY. Research and development costs are
expected to continue to increase moderately during 2006 to support product
development initiatives for SPY and clinical trials for OPTTX and LUNA.
General and administration expenses decreased by approximately $581,000
to $675,000 in Q2-2006 from $1,256,000 in Q2-2005. This overall decrease
includes a decrease of approximately $831,000 in stock based compensation
expense, offset partly by increases in salaries, professional fees, investor
relations costs and insurance. Q2-2005 Stock-based compensation expense of
approximately $908,000 related to the contractual vesting of all options
issued prior to 2005 upon completion of the Company's initial public offering.
Depreciation expense increased to approximately $41,000 in Q2-2006 from
$4,000 in Q2-2005 primarily as a result of additional computer hardware,
software and other office equipment to support the growth of the Company's
infrastructure. Amortization increased by slightly from Q2-2006 to Q2-2005 as
a result of license payments made in March 2006 which are capitalized and
amortized.
The Company had a total investment return of approximately $279,000 in
Q2-2006 on its cash and short-term investments. The increase in investment
returns over Q2-2005 is the result of an overall increase in cash and short
term investment balances following completion of the Company's initial public
offering on June 10, 2005, and higher interest rates.
Net loss increased by approximately $328,000 to approximately $2,612,000
in Q2-2006 from approximately $2,284,000 in Q2-2005 primarily as a result of
an increase in sales and marketing costs of approximately $897,000, an
increase in research and development expenses of approximately $293,000, a
decrease in general and administrative expenses of approximately $581,000,
offset partially by an increase in investment returns of approximately
$189,000. Net loss in Q2-2006 increased by approximately $237,000 from Q1-2006
primarily as a result of increases in sales and marketing and general and
administration expenses, partially offset by increased gross profit and
exchange gains and reduced research and development expenses.
Six Months Ended June 30, 2006 "Q2-YTD" Compared to Six Months Ended
June 30 2005 "YTD-2005"
Revenue in YTD 2006 was approximately $1,027,000, or 469% of YTD 2005
revenue of approximately $219,000. This included an increase in procedure
based revenue from approximately $76,000 to approximately $829,000 due
primarily to the increasing installed based in the US.
Sales and marketing expenses increased to approximately $1,954,000 in YTD
2006 from approximately $402,000 in YTD 2005 primarily due to the expansion of
commercialization activities in the US.
Research and development expenses increased to approximately $2,626,000
in YTD 2006 from approximately $1,668,000 in YTD 2005 primarily due to
increases in salary expenses relating to engineers hired to increase product
development capacity, clinical and regulatory staff to accelerate OPTTX and
LUNA programs, expenses associated with the SPY patient registry and visionary
programs, and patent and trademark costs incurred to protect developments in
OPTTX and LUNA, and expanded applications of SPY.
General and administration expenses decreased from approximately
$1,689,000 in YTD 2005 to approximately $1,242,000 in YTD 2006 primarily as a
result of a significant reduction in stock based compensation expense stemming
from the contractual vesting of all pre-2005 options upon the initial public
offering completed in YTD 2005. The reduction in stock based compensation was
offset by general increases in administrative costs to support the commercial
launch of SPY in the US, and public company costs.
As at June 30, 2006 the Company had cash, cash equivalents and short-term
investments of approximately $22,626,000, a decrease of approximately
$2,670,000 over March 31, 2006. The decrease was primarily the result of the
cash used in operations of 2,022,000 and cash invested in property and
equipment and licenses of $679,000 offset slightly by employee stock option
proceeds of approximately $31,000 during the Q2-2006. Cash, cash equivalents
and short-term investments of $22,626,000 at June 30, 2006 were approximately
$145,000 lower than at December 31, 2005 as the operating losses and
investments in property plant and equipment in the first six months of 2006
were almost entirely offset by the proceeds from the exercise of warrants in
March 2006.
As at August 1, 2006 there were a total of 19,708,784 common shares
(21,335,872 on a fully diluted basis) and no preferred shares outstanding.
Conference call
Novadaq will host a conference call and live webcast on Tuesday, August
8, 2006 at 4:30 p.m. E.T. to discuss its second quarter 2006 results. To
access the conference call by telephone, dial 416-644-3417 or 1-800-814-4861.
Please connect approximately ten minutes prior to the beginning of the call to
ensure participation. The conference call will be archived for replay until
August 15, 2006 at midnight. To access the archived conference call, dial
416-640-1917 or 1-877-289-8525 and enter the reservation number 21197987
followed by the number sign.
A live audio webcast of the conference call will be available at
www.novadaq.com. Please connect at least ten minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above website for 90
days.
About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery,
LUNA(TM) is designed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.
This press release contains certain information that may constitute
forward-looking information within the meaning of securities laws. In some
cases, forward-looking information can be identified by the use of terms such
as "may", "will", "should", "expect", "plan", "anticipate", "believe",
"intend", "estimate", "predict", "potential", "continue" or other similar
expressions concerning matters that are not historical facts. Forward-looking
information may relate to management's future outlook and anticipated events
or results, and may include statements or information regarding the future
financial position, business strategy and strategic goals, research and
development activities, projected costs and capital expenditures, financial
results, research and clinical testing outcomes, and plans and objectives of
or involving Novadaq. Particularly, information regarding future sales and
marketing activities, future revenues and research and development activities,
expectations for regulatory approval and commercial launch of the OPTTX
System, as well as the Company's plans for each of the SPY, OPTTX and Luna
Systems, is forward-looking information.
Forward-looking information is based on certain factors and assumptions
regarding, among other things, market acceptance and the rate of market
penetration of Novadaq's SPY System, the clinical results of the use of the
SPY System, the results from clinical tests of the OPTTX System, the
likelihood of regulatory approval in Europe for the OPTTX System, and
potential opportunities in the AMD treatment market, and potential
opportunities in image guided conventional and minimally invasive urological
applications including nerve-sparing radical prostatectomy. While the Company
considers these assumptions to be reasonable based on information currently
available to it, they may prove to be incorrect.
Forward looking-information is subject to certain factors, including
risks and uncertainties that could cause actual results to differ materially
from what we currently expect. These factors include risks relating to the
transition from research and development activities to commercial activities,
market acceptance and adoption of the SPY System, dependence on key suppliers
for components of the SPY System and the OPTTX System, regulatory and clinical
risks, risks relating to the protection of intellectual property, risks
inherent in the conduct of research and development activities, including the
risk of unfavorable or inconclusive clinical trial outcomes, potential product
liability, competition and the risks posed by potential technological
advances, and risks relating to fluctuations in the exchange rate between the
US dollar and the Canadian dollar.
You should not place undue importance on forward-looking information and
should not rely upon this information as of any other date. While Novadaq may
elect to, Novadaq is under no obligation and does not undertake to update this
information at any particular time.
This press release was prepared from information available to August 1,
2006.
Summary financial statements attached:
For complete financial statements please go to www.sedar.com
<<
NOVADAQ TECHNOLOGIES INC.
Incorporated under the laws of Canada
BALANCE SHEETS
(expressed in U.S.$)
Unaudited
As at As at
June 30, December 31,
2006 2005
$ $
-------------------------------------------------------------------------
ASSETS
Current
Cash and cash equivalents 71,545 750,726
Short-term investments 22,554,767 22,023,537
Accounts receivable 133,268 233,977
Investment tax credits receivable 5,221 41,341
Prepaid expenses and other receivables 684,386 553,534
Inventory 55,578 410,064
-------------------------------------------------------------------------
Total current assets 23,504,765 24,013,179
-------------------------------------------------------------------------
Property, plant and equipment, net 1,744,202 464,484
Deferred charges 72,069 11,259
Licenses, net 2,826,454 3,030,711
-------------------------------------------------------------------------
28,147,490 27,519,633
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities 1,458,893 1,432,455
Current portion of deferred revenue 37,351 37,351
-------------------------------------------------------------------------
Total current liabilities 1,496,244 1,469,806
-------------------------------------------------------------------------
Deferred revenue 3,113 21,789
-------------------------------------------------------------------------
Total liabilities 1,499,357 1,491,595
-------------------------------------------------------------------------
Shareholders' equity
Share capital 51,718,295 46,255,988
Contributed surplus 3,556,683 3,411,851
Deficit (28,626,845) (23,639,801)
-------------------------------------------------------------------------
Total shareholders' equity 26,648,133 26,028,038
-------------------------------------------------------------------------
28,147,490 27,519,633
-------------------------------------------------------------------------
-------------------------------------------------------------------------
NOVADAQ TECHNOLOGIES INC.
STATEMENTS OF LOSS AND DEFICIT
(expressed in U.S.$)
Unaudited
Three months ended Six months ended
June 30, June 30,
2006 2005 2006 2005
$ $ $ $
-------------------------------------------------------------------------
Revenue 509,260 64,057 1,027,486 219,475
Cost of sales 212,035 41,271 497,907 77,570
-------------------------------------------------------------------------
Gross profit 297,225 22,786 529,579 141,905
-------------------------------------------------------------------------
Operating expenses
Sales and marketing 1,198,051 300,889 1,954,241 402,621
Research and
development 1,241,658 948,924 2,625,162 1,667,573
General and
administration 674,604 1,255,573 1,242,108 1,689,146
Depreciation 40,644 3,702 77,610 11,968
Amortization 109,660 106,680 219,257 211,963
Loss (gain) on
foreign exchange (76,080) (218,829) (76,522) (211,354)
-------------------------------------------------------------------------
3,188,537 2,396,938 6,041,857 3,771,917
-------------------------------------------------------------------------
Loss before the
following (2,891,312) (2,374,152) (5,512,278) (3,630,012)
Other income - - 60,896 -
Interest income 279,305 90,153 464,339 124,475
-------------------------------------------------------------------------
Net loss for the
year (2,612,007) (2,283,999) (4,987,043) (3,505,537)
Deficit, beginning
of year (26,014,838) (17,986,881) (23,639,801) (16,765,343)
-------------------------------------------------------------------------
Deficit, end of
year (28,626,845) (20,270,880) (28,626,845) (20,270,880)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and diluted
loss per share (0.13) (0.14) (0.26) (0.23)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
NOVADAQ TECHNOLOGIES INC.
STATEMENTS OF CASH FLOWS
(expressed in U.S.$)
Unaudited
Three months ended Six months ended
June 30, June 30,
2006 2005 2006 2005
$ $ $ $
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for
the period (2,612,007) (2,283,999) (4,987,043) (3,505,537)
Add (deduct) items
not involving cash
Depreciation and
amortization 248,302 118,421 456,623 235,307
Stock based
compensation 76,995 908,331 144,832 1,068,940
-------------------------------------------------------------------------
(2,286,710) (1,257,247) (4,385,588) (2,201,290)
Net change in
non-cash working
capital balances
related to
operations 264,678 307,541 307,416 1,507,474
-------------------------------------------------------------------------
Cash (used) in
operating
activities (2,022,032) (949,706) (4,078,172) (693,816)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Issuance of common
shares 30,565 18,247,623 5,462,307 18,247,623
-------------------------------------------------------------------------
Cash provided by
financing
activities 30,565 18,247,623 5,462,307 18,247,623
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Purchase of property,
plant and
equipment (678,577) (89,566) (1,517,085) (31,068)
Purchase of licenses - (125,000) (15,000) (125,000)
Investments in
short-term inv.,
net 1,819,352 (17,541,464) (531,230) (17,603,255)
-------------------------------------------------------------------------
Cash provided by
(used in)
investing 1,140,775 (17,756,030) (2,063,315) (17,830,918)
-------------------------------------------------------------------------
Net increase
(decrease) in
cash and cash
equivalents
during the period (850,692) (458,113) (679,181) (277,111)
Cash and cash equiv.
beginning of period 922,237 615,382 750,726 434,380
-------------------------------------------------------------------------
Cash and cash
equivalents,
end of period 71,545 157,269 71,545 157,269
-------------------------------------------------------------------------
-------------------------------------------------------------------------
>>
%SEDAR: 00022069E
Novadaq Reports Financial Results For Second Quarter Of 2006
Novadaq Technologies Inc. on 6ix
Story so far
Earlier from Novadaq Technologies
- Novadaq to hold second quarter 2006 conference call and webcast
- Novadaq Meets Key Commercialization Milestone with 50th SPY System
- Novadaq to present at Orion Securities Annual Healthcare Conference
- Novadaq to present at Pacific Growth Equities Life Sciences Growth Conference
- Novadaq announces LUNA highlights from AUA 2006
Later from Novadaq Technologies
- Novadaq hires Divisional Vice President of Sales, Cardiac
- Novadaq Announces Luna System as Subject of Best Scientific Paper Award at the World Conference of Endourology
- Novadaq Announces European Distribution Contract with Kodak
- Novadaq updates on OPTTX clinical results as presented at this year's joint American Society of Retina Specialists and European Vitreo Retinal Society meeting
- Novadaq to present at UBS Global Life Sciences Conference
Follow Novadaq Technologies into a list and get an email when it puts out news.
Follow Novadaq Technologies